Skip to main content
Journal cover image

Sodium-Glucose Cotransporter 2 Inhibitors and Management of Refractory Hypomagnesemia Without Overt Urinary Magnesium Wasting: A Report of 2 Cases.

Publication ,  Journal Article
Shah, CV; Robbins, TS; Sparks, MA
Published in: Kidney Med
October 2022

Sodium-glucose cotransporter 2 (SGLT2) inhibitor have become widely used in patients with diabetes, heart failure, and kidney disease to improve clinical outcomes and diminish hospitalizations. They have also been associated with increased serum magnesium levels in patients with type 2 diabetes. The use of SGLT2 inhibitors resulted in improved magnesium homeostasis in a series of patients with refractory hypomagnesemia with urinary magnesium wasting. However, the role of SLGT2 inhibitors in patients with hypomagnesemia without urinary magnesium wasting remains unexplored. We report 2 cases with refractory hypomagnesemia without significant urinary magnesium wasting and dramatically improved serum magnesium levels after the initiation of SGLT2 inhibitors. Case 1 achieved independence from weekly intravenous magnesium infusions and reached sustainably greater serum magnesium levels with decreased oral magnesium supplementation and increased urinary fractional excretion of magnesium. Case 2 demonstrated improved serum magnesium levels with reduced oral magnesium supplementation without significant reduction in urinary fractional excretion of magnesium. These findings not only expand the use of SGLT2 inhibitors but also open the door for further studies to better understand the pathophysiology of how magnesium homeostasis is altered with inhibition of SGLT2.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Kidney Med

DOI

EISSN

2590-0595

Publication Date

October 2022

Volume

4

Issue

10

Start / End Page

100533

Location

United States

Related Subject Headings

  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Shah, C. V., Robbins, T. S., & Sparks, M. A. (2022). Sodium-Glucose Cotransporter 2 Inhibitors and Management of Refractory Hypomagnesemia Without Overt Urinary Magnesium Wasting: A Report of 2 Cases. Kidney Med, 4(10), 100533. https://doi.org/10.1016/j.xkme.2022.100533
Shah, Chintan V., T Scott Robbins, and Matthew A. Sparks. “Sodium-Glucose Cotransporter 2 Inhibitors and Management of Refractory Hypomagnesemia Without Overt Urinary Magnesium Wasting: A Report of 2 Cases.Kidney Med 4, no. 10 (October 2022): 100533. https://doi.org/10.1016/j.xkme.2022.100533.
Shah, Chintan V., et al. “Sodium-Glucose Cotransporter 2 Inhibitors and Management of Refractory Hypomagnesemia Without Overt Urinary Magnesium Wasting: A Report of 2 Cases.Kidney Med, vol. 4, no. 10, Oct. 2022, p. 100533. Pubmed, doi:10.1016/j.xkme.2022.100533.
Journal cover image

Published In

Kidney Med

DOI

EISSN

2590-0595

Publication Date

October 2022

Volume

4

Issue

10

Start / End Page

100533

Location

United States

Related Subject Headings

  • 3202 Clinical sciences